A Phase 2b, Double blind, Randomized, Parallel Group, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults with Chronic Hepatitis C Virus Infection

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007456-96

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the efficacy of two oral doses of GS 9450 to placebo in subjects with chronic HCV infection as evidenced by histologic response (at least a 2-point decrease in Knodell necroinflammatory score with no concurrent worsening in the Knodell fibrosis score) at Week 24.


Critère d'inclusion

  • Chronic hepatitis C virus infection